Galmed Pharma (GLMD) Tops Q3 EPS by 3c

Galmed Pharma (NASDAQ: GLMD) reported Q3 EPS of ($0.23), $0.03 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $330 thousand.

For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.

You May Also Be Interested In

• Greenbrier Cos. (GBX) Reports In-Line Q3 EPS
• Biogen expects $164M R&D charge to hit Q2 2026 earnings
• Bassett Furniture Industries (BSET) Tops Q2 EPS by 1c, Misses on Revenue